Stephens Consulting, LLC Crinetics Pharmaceuticals, Inc. Transaction History
Stephens Consulting, LLC
- $399 Billion
- Q1 2025
A detailed history of Stephens Consulting, LLC transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Stephens Consulting, LLC holds 30 shares of CRNX stock, worth $912. This represents 0.0% of its overall portfolio holdings.
Number of Shares
30Holding current value
$912% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding CRNX
# of Institutions
257Shares Held
82.5MCall Options Held
26.1KPut Options Held
11.8K-
Vanguard Group Inc Valley Forge, PA9.09MShares$276 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$190 Million0.01% of portfolio
-
Driehaus Capital Management LLC Chicago, IL6.14MShares$187 Million3.06% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.41MShares$165 Million0.03% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA4.29MShares$130 Million10.24% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $1.64B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...